DR. HENRY JOSEPH HORACEK, M.D.
Neurology at Carmel Commons Blvd, Charlotte, NC
License number
North Carolina 24599
Category
Neurology
Type
Neurology
License number
North Carolina 24599
Category
Neurology
Type
Neurology with Special Qualifications in Child Neurology
License number
North Carolina 24599
Category
Neurology
Type
Neurodevelopmental Disabilities
Address
Address
10716 Carmel Commons Blvd SUITE 120, Charlotte, NC 28226
Phone
(704) 542-9590
Personal information
See more information about HENRY JOSEPH HORACEK at radaris.comName
Address
Phone
5927 Gold Wagon Ln, Charlotte, NC 28227
Professional information
Henry Joseph Horacek, Charlotte NC
Specialties:
Pediatric Neurologist
Address:
10716 Carmel Commons Blvd, Charlotte, NC 28226
Board certifications:
American Board of Psychiatry and Neurology Certification in Psychiatry (Psychiatry and Neurology), American Board of Psychiatry and Neurology Sub-certificate in Child and Adolescent Psychiatry (Psychiatry and Neurology)
Dr. Henry J Horacek, Charlotte NC - MD (Doctor of Medicine)
Specialties:
Child & Adolescent Psychiatry
Address:
Center-Neurological Health/Lear
10716 Carmel Commons Blvd SUITE 120, Charlotte 28226
(704) 542-9590 (Phone)
10716 Carmel Commons Blvd SUITE 120, Charlotte 28226
(704) 542-9590 (Phone)
Certifications:
Child & Adolescent Psychiatry, 1989, Psychiatry, 1985
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of North Carolina At Chapel Hill
Graduated: 1979
Nc Meml Hospital
Graduated: 1980
Graduated: 1982
Duke Med Center
Graduated: 1984
University of North Carolina At Chapel Hill
Graduated: 1979
Nc Meml Hospital
Graduated: 1980
Graduated: 1982
Duke Med Center
Graduated: 1984
Extended Release Formulation And Methods Of Treating Adrenergic Dysregulation
US Patent:
2010017, Jul 8, 2010
Filed:
Dec 23, 2009
Appl. No.:
12/645772
Inventors:
Henry Joseph Horacek - Charlotte NC, US
Min Michael He - Ellicott City MD, US
Moise A. Khayrallah - Morrisville NC, US
Min Michael He - Ellicott City MD, US
Moise A. Khayrallah - Morrisville NC, US
International Classification:
A61K 9/14, A61K 31/4168, C07D 233/50, A61P 9/12, A61P 9/04, A61P 25/06, A61P 25/02, A61P 25/30, A61P 3/04, A61P 25/18
US Classification:
424488, 514398, 5483331
Abstract:
A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a α-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours (e.g., no more than once about every 24 hours) to a subject having a steady state plasma concentration of the α-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.
Extended Release Formulation And Method Of Treating Adrenergic Dysregulation
US Patent:
2010006, Mar 11, 2010
Filed:
Nov 10, 2009
Appl. No.:
12/615477
Inventors:
Henry Joseph Horacek - Charlotte NC, US
Min Michael He - Ellicott City MD, US
Moise A. Khayrallah - Morrisville NC, US
Min Michael He - Ellicott City MD, US
Moise A. Khayrallah - Morrisville NC, US
International Classification:
A61K 31/415
US Classification:
514401
Abstract:
A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a a2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours to a subject having a steady state plasma concentration of the a2-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.
Extended Release Formulation And Method Of Treating Adrenergic Dysregulation
US Patent:
2009008, Apr 2, 2009
Filed:
Jun 6, 2008
Appl. No.:
12/134444
Inventors:
Henry Joseph Horacek - Charlotte NC, US
Min Michael He - Ellicott City MD, US
Moise A. Khayrallah - Morrisville NC, US
Min Michael He - Ellicott City MD, US
Moise A. Khayrallah - Morrisville NC, US
Assignee:
Addrenex Pharmaceuticals, Inc. - Durham NC
International Classification:
A61K 31/4168, A61K 9/00, A61P 25/00, A61K 47/38
US Classification:
424488, 514778, 514781, 514401
Abstract:
A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a α-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours to a subject having a steady state plasma concentration of the α-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.
Extended Release Formulation And Methods Of Treating Adrenergic Dysregulation
US Patent:
2011024, Oct 6, 2011
Filed:
Apr 8, 2011
Appl. No.:
13/082724
Inventors:
Henry Joseph Horacek - Charlotte NC, US
Min Michael He - Ellicott City MD, US
Moise A. Khayrallah - Morrisville NC, US
Min Michael He - Ellicott City MD, US
Moise A. Khayrallah - Morrisville NC, US
International Classification:
A61K 31/4168, A61P 5/26
US Classification:
514401
Abstract:
A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a α-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours to a subject having a steady state plasma concentration of the α-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.
Extended Release Formulation And Method Of Treating Adrenergic Dysregulation
US Patent:
2010020, Aug 19, 2010
Filed:
Sep 16, 2009
Appl. No.:
12/560648
Inventors:
Henry Joseph Horacek - Charlotte NC, US
Min Michael He - Ellicott City MD, US
Moise A. Khayrallah - Morrisville NC, US
Min Michael He - Ellicott City MD, US
Moise A. Khayrallah - Morrisville NC, US
International Classification:
A61K 31/4168, A61K 9/10, A61P 9/12, A61P 9/00, A61P 9/04, A61P 25/02, A61P 3/10, A61P 25/18, A61P 25/00, A61P 25/14
US Classification:
424488, 514401
Abstract:
A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a α-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours to a subject having a steady state plasma concentration of the α-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.